CoreLab Partners completes first ever regulatory mandated Thorough QT study in the Asia Pacific Rim

September 13, 2015

According to a survey published in the Journal of the American Board of Family Medicine, many people still hope to find a better treatment for their migraines, with more than a quarter dissatisfied with their treatment and fewer than a fifth of people who suffer migraines describing themselves as "very satisfied" with their treatment.

A novel, water-soluble, buffered diclofenac potassium powder, CAMBIA?? is the only prescription non - steroidal anti-inflammatory drug (NSAID) available for the acute treatment of migraine.  Engineered using Dynamic Buffering Technology?? (DBT), a patented absorption-enhancing technology developed by APR Applied Pharma Research S.A., CAMBIA?? is specifically designed for fast, effective relief from the symptoms of migraine. CAMBIA?? enters the bloodstream quickly and readily achieves peak plasma concentrations, providing pain relief in fifteen minutes for some patients.

SOURCE Nautilus Neurosciences, Inc.